Primarily focused on developing individualized cancer therapy, BioNTech is a biotechnology company located in Mainz, Germany.
Their method revolves around several platforms in medicine; mRNA Therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators. Coupled with their approach to patient specific needs, they have seen success in providing unique treatments.
- Sequencing patient's tumor
- Mapping of mutations
- Bioinformatic algorithms
- Selection of neoepitopes
BNT162 is BioNTech’s mRNA vaccine program aimed at preventing COVID-19 infection. It is the first product candidate from Project Lightspeed and leverages BioNTech’s proprietary mRNA platforms for infectious diseases, its fully-owned GMP manufacturing infrastructure for mRNA vaccine production, and its global clinical development capabilities, drawing on BioNTech’s network of global collaborators. BioNTech is partnered with Pfizer for co-development and distribution of BNT162 and with Fosun Pharma on the vaccine development in China.
Timeline
The European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.
Funding rounds
Patents
Products
People
Özlem Türeci
Chief Medical Officer
Ryan Richardson
Chief Strategy Officer
Sean Marett
Chief Business and Chief Commercial Officer
Sierk Poetting
Chief Financial Officer and Chief Operating Officer
Ugur Sahin
Chief Executive Officer
Further reading
Documentaries, videos and podcasts
Companies
News
References
CompanyCompany attributes
Cancer immunotherapy
Biotechnology
Vaccine
Drug discovery
Therapeutics
Medical diagnostics
Research and development
Mainz
Germany
B2C
Ugur Sahin
Incorporation (business)
Johannes Gutenberg University of Mainz
Jebsen Capital
Invus
MIG Fonds
European Investment Bank
Bill & Melinda Gates Foundation
Fidelity Investments
Temasek Holdings
Sanofi
Kernal Biologics
Series B roundOther attributes
Categories
Related Topics
Contributors
- 1
Nico Faraguna
Video game fan with a passion for technology and pop culture. I make plastic rock climbing routes, too. - 2
Jason D. Rowley
Former Data Acquisition Lead @ Golden (Recursion Inc.). Excited about open knowledge and pulling the future forward. - 3
Carla Faraguna
Golden People and Operations. - 4
Meredith Hanel
Medical Genetics PhD, following life science applications that improve the health of humans and our planet. - 5
Henry Ogolla
Passionate about reading and writing. - 6
Joe Burns
My name is Joe Burns. I love technology, sports and writing! - 7
Erin Scherfner
loading information... - 8
Marie Gabrielle Laguna- Bedia
Co-founder and Managing Partner of Eternus Global. Physician of internal medicine, app developer and entrepreneur - 9
Aime Anne Nisay
QA Engineer of web and mobile applications - 10
Aleksander Holm
Interested in understanding the world we live in.